These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33657816)

  • 21. Germline RAD51C mutations in ovarian cancer susceptibility.
    Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
    Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline mutations in RAD51C in Jewish high cancer risk families.
    Kushnir A; Laitman Y; Shimon SP; Berger R; Friedman E
    Breast Cancer Res Treat; 2012 Dec; 136(3):869-74. PubMed ID: 23117857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
    Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
    Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.
    Pelttari LM; Shimelis H; Toiminen H; Kvist A; Törngren T; Borg Å; Blomqvist C; Bützow R; Couch F; Aittomäki K; Nevanlinna H
    Clin Genet; 2018 Mar; 93(3):595-602. PubMed ID: 28802053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
    Clague J; Wilhoite G; Adamson A; Bailis A; Weitzel JN; Neuhausen SL
    PLoS One; 2011; 6(9):e25632. PubMed ID: 21980511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
    Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D
    J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
    Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
    Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
    Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
    Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
    J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.
    Thompson ER; Boyle SE; Johnson J; Ryland GL; Sawyer S; Choong DY; kConFab ; Chenevix-Trench G; Trainer AH; Lindeman GJ; Mitchell G; James PA; Campbell IG
    Hum Mutat; 2012 Jan; 33(1):95-9. PubMed ID: 21990120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.
    Golmard L; Castéra L; Krieger S; Moncoutier V; Abidallah K; Tenreiro H; Laugé A; Tarabeux J; Millot GA; Nicolas A; Laé M; Abadie C; Berthet P; Polycarpe F; Frébourg T; Elan C; de Pauw A; Gauthier-Villars M; Buecher B; Stern MH; Stoppa-Lyonnet D; Vaur D; Houdayer C
    Eur J Hum Genet; 2017 Dec; 25(12):1345-1353. PubMed ID: 29255180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer.
    Lhotova K; Stolarova L; Zemankova P; Vocka M; Janatova M; Borecka M; Cerna M; Jelinkova S; Kral J; Volkova Z; Urbanova M; Kleiblova P; Machackova E; Foretova L; Hazova J; Vasickova P; Lhota F; Koudova M; Cerna L; Tavandzis S; Indrakova J; Hruskova L; Kosarova M; Vrtel R; Stranecky V; Kmoch S; Zikan M; Macurek L; Kleibl Z; Soukupova J
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32295079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic testing by cancer site: ovary.
    Weissman SM; Weiss SM; Newlin AC
    Cancer J; 2012; 18(4):320-7. PubMed ID: 22846732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations.
    Yao H; Li N; Yuan H
    BMC Cancer; 2022 Dec; 22(1):1337. PubMed ID: 36544182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hereditary Ovarian Cancer and Risk Reduction.
    Andrews L; Mutch DG
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():31-48. PubMed ID: 28254144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.
    Li N; McInerny S; Zethoven M; Cheasley D; Lim BWX; Rowley SM; Devereux L; Grewal N; Ahmadloo S; Byrne D; Lee JEA; Li J; Fox SB; John T; Antill Y; Gorringe KL; James PA; Campbell IG
    J Natl Cancer Inst; 2019 Dec; 111(12):1332-1338. PubMed ID: 30949688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.